Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
30/05/2024 | 08:30 | GlobeNewswire Inc. | Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024 | EU:IVA | Inventiva |
30/05/2024 | 08:30 | GlobeNewswire Inc. | Combined General Meeting of June 20, 2024 - Availability of the preparatory documents | EU:IVA | Inventiva |
30/05/2024 | 08:30 | GlobeNewswire Inc. | Information relative au nombre total de droits de vote et d’actions composant le capital social au 13 mai 2024 | EU:IVA | Inventiva |
30/05/2024 | 08:30 | GlobeNewswire Inc. | Assemblée Générale Mixte du 20 juin 2024 - Modalités de mise à disposition des documents préparatoires | EU:IVA | Inventiva |
22/05/2024 | 22:00 | GlobeNewswire Inc. | Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024 | EU:IVA | Inventiva |
21/05/2024 | 22:00 | GlobeNewswire Inc. | Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update | EU:IVA | Inventiva |
21/05/2024 | 22:00 | GlobeNewswire Inc. | Inventiva publie ses informations financières du 1 ͤ ͬ trimestre 2024¹ et fait un point sur ses activités | EU:IVA | Inventiva |
16/05/2024 | 22:00 | GlobeNewswire Inc. | Inventiva annonce la recommandation positive du quatrième DMC de l’étude clinique NATiV3 Phase III avec lanifibranor dans la MASH/NASH | EU:IVA | Inventiva |
16/05/2024 | 22:00 | GlobeNewswire Inc. | Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH | EU:IVA | Inventiva |
13/05/2024 | 08:30 | GlobeNewswire Inc. | Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor | EU:IVA | Inventiva |
13/05/2024 | 08:30 | GlobeNewswire Inc. | Inventiva annonce la publication dans Nature Communications de résultats complémentaires de l’étude clinique de Phase II NATIVE démontrant l’amélioration de marqueurs de santé cardiométabolique chez les patients atteints de MASH/NASH traité | EU:IVA | Inventiva |
03/04/2024 | 22:00 | GlobeNewswire Inc. | Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F | EU:IVA | Inventiva |
03/04/2024 | 22:00 | GlobeNewswire Inc. | Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F ») | EU:IVA | Inventiva |
28/03/2024 | 08:00 | GlobeNewswire Inc. | Inventiva announces the nomination of Andre Turenne as Director | EU:IVA | Inventiva |
28/03/2024 | 08:00 | GlobeNewswire Inc. | Inventiva annonce la nomination d’Andre Turenne en tant qu’administrateur | EU:IVA | Inventiva |
27/03/2024 | 21:00 | GlobeNewswire Inc. | Inventiva reports its 2023 full-year results | EU:IVA | Inventiva |
27/03/2024 | 21:00 | GlobeNewswire Inc. | Inventiva publie ses résultats annuels 2023 | EU:IVA | Inventiva |
22/03/2024 | 21:00 | GlobeNewswire Inc. | Inventiva annonce la date de publication et de présentation de ses résultats financiers 2023 | EU:IVA | Inventiva |
22/03/2024 | 21:00 | GlobeNewswire Inc. | Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results | EU:IVA | Inventiva |
18/03/2024 | 21:00 | GlobeNewswire Inc. | Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète de type 2 | EU:IVA | Inventiva |
18/03/2024 | 21:00 | GlobeNewswire Inc. | Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D | EU:IVA | Inventiva |
13/03/2024 | 21:00 | GlobeNewswire Inc. | Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D | EU:IVA | Inventiva |
13/03/2024 | 21:00 | GlobeNewswire Inc. | Inventiva annonce la présentation des résultats de son étude clinique de Phase IIa LEGEND combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de DT2 | EU:IVA | Inventiva |
07/03/2024 | 22:00 | GlobeNewswire Inc. | Inventiva annonce la reprise du screening dans l’étude clinique de Phase III, NATiV3, évaluant lanifibranor dans la NASH | EU:IVA | Inventiva |
07/03/2024 | 22:00 | GlobeNewswire Inc. | Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed | EU:IVA | Inventiva |
15/02/2024 | 22:35 | GlobeNewswire Inc. | Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3 | EU:IVA | Inventiva |
15/02/2024 | 22:35 | GlobeNewswire Inc. | Inventiva publie ses informations financières préliminaires pour l’exercice fiscal 2023¹ et fait le point sur son étude clinique NATiV3 | EU:IVA | Inventiva |
24/01/2024 | 22:15 | GlobeNewswire Inc. | Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux | EU:IVA | Inventiva |
24/01/2024 | 22:15 | GlobeNewswire Inc. | Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux | EU:IVA | Inventiva |
10/01/2024 | 22:00 | GlobeNewswire Inc. | Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank | EU:IVA | Inventiva |